Agilent Technologies (NYSE:A) Given New $185.00 Price Target at Royal Bank Of Canada

Agilent Technologies (NYSE:A) had its price objective hoisted by analysts at Royal Bank Of Canada from $155.00 to $185.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the medical research company’s stock. Royal Bank Of Canada’s price target would suggest a potential upside of 17.03% from the company’s previous close.

A number of other equities analysts have also recently weighed in on A. Wolfe Research reissued a “hold” rating on shares of Agilent Technologies in a report on Tuesday, June 2nd. Barclays increased their price objective on Agilent Technologies from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. HSBC dropped their price objective on Agilent Technologies from $180.00 to $165.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Sanford C. Bernstein initiated coverage on shares of Agilent Technologies in a research note on Friday, June 26th. They issued an “outperform” rating and a $155.00 target price for the company. Finally, TD Cowen upped their target price on shares of Agilent Technologies from $147.00 to $155.00 and gave the company a “buy” rating in a report on Thursday, May 28th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, Agilent Technologies presently has a consensus rating of “Moderate Buy” and a consensus target price of $162.12.

Agilent Technologies Price Performance

Shares of Agilent Technologies stock traded up $3.00 on Thursday, hitting $158.08. The company’s stock had a trading volume of 683,712 shares, compared to its average volume of 2,225,178. The company has a quick ratio of 1.62, a current ratio of 2.10 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $44.65 billion, a P/E ratio of 31.60, a price-to-earnings-growth ratio of 2.73 and a beta of 1.25. The firm has a fifty day moving average price of $139.16 and a 200-day moving average price of $126.65. Agilent Technologies has a 52-week low of $108.35 and a 52-week high of $163.75.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.13. Agilent Technologies had a net margin of 19.55% and a return on equity of 24.33%. The company had revenue of $1.88 billion for the quarter, compared to the consensus estimate of $1.84 billion. During the same quarter in the prior year, the firm earned $1.37 earnings per share. The company’s revenue for the quarter was up 8.1% compared to the same quarter last year. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, equities research analysts expect that Agilent Technologies will post 6.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. California State Teachers Retirement System grew its holdings in Agilent Technologies by 12,343.3% in the 2nd quarter. California State Teachers Retirement System now owns 54,577,058 shares of the medical research company’s stock valued at $7,249,471,000 after buying an additional 54,138,451 shares during the period. Norges Bank purchased a new position in shares of Agilent Technologies during the 4th quarter worth about $549,158,000. Bank of New York Mellon Corp boosted its position in shares of Agilent Technologies by 87.4% in the second quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company’s stock worth $695,227,000 after acquiring an additional 2,440,360 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of Agilent Technologies in the second quarter worth approximately $260,101,000. Finally, AQR Capital Management LLC grew its holdings in Agilent Technologies by 424.1% in the second quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company’s stock valued at $240,956,000 after purchasing an additional 1,652,244 shares during the period. Hedge funds and other institutional investors own 87.41% of the company’s stock.

Key Headlines Impacting Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent reported third-quarter revenue of $1.88 billion, up 8.1% year over year and above the $1.84 billion consensus estimate. Adjusted EPS was $1.62, ahead of the $1.49 analyst expectation and up from $1.37 a year earlier. GAAP net income increased to $362 million, or $1.28 per share. Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: Management raised fiscal 2026 adjusted EPS guidance to $6.18-$6.21, above the $6.06 consensus, and expects approximately $7.5 billion in revenue. The improved outlook reflects better demand for tools used in laboratory research, drug development and related applications. Agilent raises annual profit forecast on improving lab tools demand
• Positive Sentiment: Results pointed to operating leverage, with operating profit reportedly rising faster than revenue and margins expanding. Cash flow was also strong, supporting Agilent’s financial flexibility and reinforcing the earnings-quality case. Agilent Technologies: Q3 Growth, Expanding Margins, And Raised Guidance
• Neutral Sentiment: Fourth-quarter adjusted EPS guidance of $1.71-$1.74 is centered around the analyst consensus, while expected revenue of approximately $2.0 billion is broadly in line. This suggests the main upside catalyst came from the third-quarter beat and full-year upgrade rather than a major near-term forecast increase. Agilent Boosts FY View on Higher 3Q Profit, Revenue
• Neutral Sentiment: Institutional ownership changes were mixed, and the shares’ elevated valuation—about 31 times earnings—leaves less room for disappointment despite the stronger outlook.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.